425 related articles for article (PubMed ID: 9697119)
1. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation.
Chen HS; Wang YF; Rayudu PV; Edgecomb P; Neill JC; Segal MM; Lipton SA; Jensen FE
Neuroscience; 1998 Oct; 86(4):1121-32. PubMed ID: 9697119
[TBL] [Abstract][Full Text] [Related]
2. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices.
Frankiewicz T; Potier B; Bashir ZI; Collingridge GL; Parsons CG
Br J Pharmacol; 1996 Feb; 117(4):689-97. PubMed ID: 8646415
[TBL] [Abstract][Full Text] [Related]
3. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
[TBL] [Abstract][Full Text] [Related]
5. The neuroprotective glycine receptor antagonist GV150526 does not produce neuronal vacuolization or cognitive deficits in rats.
Bordi F; Terron A; Reggiani A
Eur J Pharmacol; 1999 Aug; 378(2):153-60. PubMed ID: 10478627
[TBL] [Abstract][Full Text] [Related]
6. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
7. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
8. Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801.
Nakamura S; Murayama N; Noshita T; Katsuragi R; Ohno T
Eur J Pharmacol; 2006 Oct; 548(1-3):115-22. PubMed ID: 16952349
[TBL] [Abstract][Full Text] [Related]
9. Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine.
Emnett CM; Eisenman LN; Taylor AM; Izumi Y; Zorumski CF; Mennerick S
Mol Pharmacol; 2013 Dec; 84(6):935-47. PubMed ID: 24101301
[TBL] [Abstract][Full Text] [Related]
10. Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices.
Frankiewicz T; Parsons CG
Neuropharmacology; 1999 Sep; 38(9):1253-9. PubMed ID: 10471078
[TBL] [Abstract][Full Text] [Related]
11. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP.
Zajaczkowski W; Frankiewicz T; Parsons CG; Danysz W
Neuropharmacology; 1997 Jul; 36(7):961-71. PubMed ID: 9257940
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices.
Frankiewicz T; Pilc A; Parsons CG
Neuropharmacology; 2000 Feb; 39(4):631-42. PubMed ID: 10728884
[TBL] [Abstract][Full Text] [Related]
13. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses.
Xia P; Chen HS; Zhang D; Lipton SA
J Neurosci; 2010 Aug; 30(33):11246-50. PubMed ID: 20720132
[TBL] [Abstract][Full Text] [Related]
14. In vitro galantamine-memantine co-application: mechanism of beneficial action.
Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
[TBL] [Abstract][Full Text] [Related]
15. N-methyl-D-aspartate receptor-dependent long-term potentiation in CA1 region affects synaptic expression of glutamate receptor subunits and associated proteins in the whole hippocampus.
Zhong WX; Dong ZF; Tian M; Cao J; Xu L; Luo JH
Neuroscience; 2006 Sep; 141(3):1399-413. PubMed ID: 16766131
[TBL] [Abstract][Full Text] [Related]
16. Memantine selectively blocks extrasynaptic NMDA receptors in rat substantia nigra dopamine neurons.
Wu YN; Johnson SW
Brain Res; 2015 Apr; 1603():1-7. PubMed ID: 25656790
[TBL] [Abstract][Full Text] [Related]
17. Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine.
Misztal M; Frankiewicz T; Parsons CG; Danysz W
Eur J Pharmacol; 1996 Jan; 296(1):1-8. PubMed ID: 8720470
[TBL] [Abstract][Full Text] [Related]
18. MK-801 and memantine act differently on short-term memory tested with different time-intervals in the Morris water maze test.
Duda W; Wesierska M; Ostaszewski P; Vales K; Nekovarova T; Stuchlik A
Behav Brain Res; 2016 Sep; 311():15-23. PubMed ID: 27180167
[TBL] [Abstract][Full Text] [Related]
19. 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism.
Karanian DA; Baude AS; Brown QB; Parsons CG; Bahr BA
Hippocampus; 2006; 16(10):834-42. PubMed ID: 16897723
[TBL] [Abstract][Full Text] [Related]
20. Reducing conditions significantly attenuate the neuroprotective efficacy of competitive, but not other NMDA receptor antagonists in vitro.
Pringle AK; Self J; Eshak M; Iannotti F
Eur J Neurosci; 2000 Nov; 12(11):3833-42. PubMed ID: 11069578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
